Otilimab治疗类风湿关节炎的2b期剂量探索研究
这项2b期多中心随机双盲安慰剂对照研究在222例接受稳定甲氨蝶呤的活动性类风湿关节炎患者中评估抗GM-CSF抗体otilimab的疗效与安全性。
要点
- otilimab联合甲氨蝶呤总体耐受性良好,严重感染率低,无死亡或临床关注的肺部事件。
- 患者报告的疼痛与躯体功能显著改善,支持otilimab在类风湿关节炎中的进一步临床开发。
核心结论
- otilimab联合甲氨蝶呤耐受性良好,虽未达到DAS28-CRP缓解的主要终点,但疾病活动度评分较安慰剂改善,疼痛与躯体功能显著改善。
研究设计与样本
- 2b期、剂量探索、多中心、安慰剂对照研究,在14个国家64个中心开展。
- 随机化采用区组(每组6例)但未分层,研究者、患者与申办方对治疗设盲。
- 疗效与安全性在意向治疗人群中评估;研究注册号NCT02504671。
主要发现
- 逃逸治疗情况:第12周175例中86例(49%)、第24周83例中57例(69%)逃逸至otilimab 180 mg,逃逸者按原分组计为非应答者。
- 逃逸前不良事件在otilimab各剂量组为19-24例(51-65%)、安慰剂组18/37(49%);逃逸后分别为10-17例(40-61%)和22/33(67%)。
- 最常见不良事件为鼻咽炎,逃逸前otilimab组3-9例(8-24%)、安慰剂组1例(3%)。
关键数值与推荐
- 安全性终点包括不良事件与严重不良事件发生率、感染及肺部事件。
临床怎么用
- otilimab联合甲氨蝶呤在活动性类风湿关节炎中耐受性良好,严重感染率低。
- 虽未达DAS28-CRP缓解主要终点,但疾病活动度评分较安慰剂改善,疼痛与躯体功能显著改善。
- 结果支持otilimab在类风湿关节炎中进一步临床开发,尚需更大样本研究验证。
局限性
- 采用逃逸设计,逃逸者按非应答者计入原分组,可能影响疗效估计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The human monoclonal antibody otilimab inhibits granulocyte-macrophage colony-stimulating factor (GM-CSF), a key driver in immune-mediated inflammatory conditions. We aimed to evaluate the efficacy, safety, and key patient-reported outcomes related to pain in patients with active rheumatoid arthritis receiving otilimab. METHODS: This phase 2b, dose-ranging, multicentre, placebo-controlled study was done at 64 sites across 14 countries. Patients aged 18 years or older with rheumatoid arthritis who were receiving stable methotrexate were randomly assigned (1:1:1:1:1:1) to subcutaneous placebo or otilimab 22·5 mg, 45 mg, 90 mg, 135 mg, or 180 mg, plus methotrexate, once weekly for 5 weeks, then every other week until week 50. The randomisation schedule was generated by the sponsor, and patients were assigned to treatment by interactive response technology. Randomisation was blocked (block size of six) but was not stratified. Investigators, patients, and the sponsor were blinded to treatment. An unblinded administrator prepared and administered the study drug. The primary endpoint was the proportion of patients who achieved disease activity score for 28 joints with C-reactive protein (DAS28-CRP) <2·6 at week 24. Patients who were not in the otilimab 180 mg group, without a good or moderate European League Against Rheumatism response (week 12) or with DAS28-CRP >3·2 (week 24) escaped to otilimab 180 mg. Patients who escaped were treated as non-responders in their original assigned group. Safety endpoints were incidence of adverse events and serious adverse events, infections, and pulmonary events. Efficacy and safety outcomes were assessed in the intention-to-treat population. This study is registered with ClinicalTrials.gov, NCT02504671. FINDINGS: Between July 23, 2015, and Dec 29, 2017, 222 patients were randomly assigned (37 to each group). 86 (49%) of 175 escaped to otilimab 180 mg at week 12 and 57 (69%) of 83 at week 24. At week 24, the proportion of patients with DAS28-CRP <2·6 was two (5%) of 37 in the otilimab 22·5 mg group, six (16%) of 37 in the 45 mg group, seven (19%) of 37 in the 90 mg group, five (14%) of 37 in the 135 mg group, five (14%) of 37 in the 180 mg, and one (3%) of 37 in the placebo group. The largest difference was achieved with otilimab 90 mg (16·2%; odds ratio [OR] 8·39, 95% CI 0·98-72·14; p=0·053). Adverse events were reported pre-escape in 19-24 (51-65%) patients and post escape in 10-17 (40-61%) patients across otilimab dose groups and in 18 (49%) of 37 and 22 (67%) of 33 in the placebo group. The most common adverse event was nasopharyngitis: 3-9 (8-24%) in otilimab groups and one (3%) in the placebo group pre-escape and 1-3 (4-10%) in otilimab groups and seven (21%) in the placebo group post escape. Pre-escape serious adverse events were foot fracture (otilimab 45 mg); arthralgia, myocardial infarction, dizziness (otilimab 90 mg); oesophageal spasm, acute pyelonephritis (otilimab 22·5 mg), and uterine leiomyoma (otilimab 135 mg). Post-escape serious adverse events were ankle fracture (placebo) and rheumatoid arthritis (otilimab 135 mg). There were no deaths or pulmonary events of clinical concern, and rates of serious infection were low. INTERPRETATION: Otilimab plus methotrexate was well tolerated and, despite not achieving the primary endpoint of DAS28-CRP remission, there were improvements compared with placebo in disease activity scores. Of note, patients reported significant improvement in pain and physical function, supporting further clinical development of otilimab in rheumatoid arthritis. FUNDING: GlaxoSmithKline.
引用
- Buckley CD, Simón-Campos JA, Zhdan V, et al. Efficacy, patient-reported outcomes, and safety of the anti-granulocyte macrophage colony-stimulating factor antibody otilimab (GSK3196165) in patients with rheumatoid arthritis: a randomised, phase 2b, dose-ranging study. Lancet Rheumatol. 2020. PMID: 38279364. doi:10.1016/S2665-9913(20)30229-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。